On Dec. 3, 2020, Inovio Pharmaceuticals announced the execution of an agreement with Kaneka Eurogentec an affiliate of Kaneka Corp., for Eurogentec to manufacture INOVIO’s COVID-19 vaccine candidate INO-4800 at their industry-leading GMP plasmid production scales. Terms of the agreement were not disclosed.